Supplemental Method

Search strategies for PubMed, EMBASE, and Cochrane database

PubMed:28 results

Embase:68 results

('pembrolizumab':ab,ti OR 'nivolumab':ab,ti OR 'atezolizumab':ab,ti OR 'durvalumab':ab,ti OR 'tremelimumab':ab,ti OR 'avelumab':ab,ti OR 'immune checkpoint inhibitor':ab,ti OR 'immunotherapy':ab,ti OR 'programmed cell death ligand 1':ab,ti OR 'programmed death 1 receptor':ab,ti OR 'PD-1':ab,ti OR 'PD-L1':ab,ti) AND (('extensive stage' AND 'small cell' AND ('lung'/exp OR lung) AND ('cancer'/exp OR cancer)) AND ('randomized controlled trial'/exp))

Cochrane: 120 results (120 trials)

- #1 MeSH descriptor: [Small Cell Lung Carcinoma] explode all trees
- #2 "lung" AND "extensive stage" AND("Small Cell" OR "Small-Cell")
- #3 "pembrolizumab" or "nivolumab" or "atezolizumab" or "durvalumab" or "tremelimumab" or "avelumab" or "immune checkpoint inhibitor" or "immunotherapy" or "programmed cell death ligand 1" or "programmed cell death protein 1" or "PD-1" or "PD-L1"
- # 4 (#1 OR #2) AND #3

Supplemental Table 1. Quality assessment by Cochrane Collaboration's tool.

Trial	Sequence generation	Allocation concealment	Blinding	Incomplete outcome data	Selective reporting	Other source of bias
IMpower 133	Adequate	Adequate (Central allocation)	Adequatea	Adequate	Adequate	
CASPIAN	Adequate	Adequate (Central allocation)	Adequatea	Adequate	Adequate	
KEYNOTE -604	Adequate	Adequate (Central allocation)	Adequatea	Adequate	Adequate	
EA5161	Adequate	Adequate (Central allocation)	Adequatea	Inadequate ^b	Adequate	Data from the abstract

a: The sponsor, investigator and subject were aware of the treatment administration but the response to treatment was assessed by means of blinded, independent, central radiologic review.

b: Absence of data of ORR and AEs.

Supplemental Figure 1. Flowchart for trial selection

